Hayakawa H, Shimizu M, Yamawaki S
Department of Neurology and Psychiatry, Hiroshima University, School of Medicine, Japan.
Neuropharmacology. 1992 Sep;31(9):955-60. doi: 10.1016/0028-3908(92)90136-d.
The effects of repeated treatment (14 days) with electroconvulsive shock (ECS) or imipramine on binding sites on alpha 1-adrenoceptors in the rat were studied. The binding of [3H]prazosin studied with WB4101 and phentolamine, as binding inhibitors, showed the existence of two subtypes of alpha 1-adrenoceptor (alpha 1A and alpha 1B). Proportions of the alpha 1A and alpha 1B binding sites were about 3:7 in the frontal cortex and 9:1 in the hippocampus. Pretreatment of the membranes with chlorethylclonidine (CEC) almost abolished the alpha 1B binding sites. Inhibition of the binding of [3H]prazosin studied with antidepressants (imipramine, desipramine, maprotiline and mianserin) showed that these drugs bound to alpha 1-adrenoceptors with low affinity, in an apparent monophasic manner. The characteristics of the alpha 1A and alpha 1B binding sites were studied by the binding assay with [3H]prazosin, in the presence of a small concentration (2 nM) of WB4101 to mask the alpha 1A binding sites, as well as the assay without WB4101, for the total alpha 1-adrenoceptor (alpha 1A and alpha 1B) binding. Repeated treatment with electroconvulsive shock increased but that with imipramine decreased, the density of the alpha 1B binding sites in the frontal cortex, without change of the affinity. Neither treatment affected the alpha 1A binding sites in the frontal cortex. The alpha 1-adrenoceptors (alpha 1A and alpha 1B) in the hippocampus were not affected at all by these repeated treatments. The electroconvulsive shock-induced increase in the alpha 1B binding sites in the frontal cortex of the rat could contribute to differences in clinical effects between electroconvulsive shock and antidepressant drugs.
研究了电休克(ECS)或丙咪嗪重复治疗(14天)对大鼠α1 - 肾上腺素能受体结合位点的影响。用作为结合抑制剂的WB4101和酚妥拉明研究[3H]哌唑嗪的结合,显示存在两种α1 - 肾上腺素能受体亚型(α1A和α1B)。额叶皮质中α1A和α1B结合位点的比例约为3:7,海马中为9:1。用氯乙可乐定(CEC)预处理膜几乎消除了α1B结合位点。用抗抑郁药(丙咪嗪、地昔帕明、马普替林和米安色林)研究对[3H]哌唑嗪结合的抑制作用,结果表明这些药物以低亲和力、明显单相的方式与α1 - 肾上腺素能受体结合。通过在存在低浓度(2 nM)WB4101以掩盖α1A结合位点的情况下用[3H]哌唑嗪进行结合测定,以及在没有WB4101的情况下进行测定以检测总的α1 - 肾上腺素能受体(α1A和α1B)结合,研究了α1A和α1B结合位点的特性。电休克重复治疗增加了额叶皮质中α1B结合位点的密度,但丙咪嗪重复治疗则使其降低,亲和力未改变。两种治疗均未影响额叶皮质中的α1A结合位点。这些重复治疗对海马中的α1 - 肾上腺素能受体(α1A和α1B)完全没有影响。大鼠额叶皮质中电休克诱导的α1B结合位点增加可能导致电休克与抗抑郁药临床效果的差异。